

# COVID-19 UPDATE


## Facts & Figures

Issued September 02, 2021


### Last Contagion Figures

- **September 01: 647,105 7-day average new cases**, compared to 659,516 a week ago and 599,815 a month ago. Now confirmed **218,297,310 cases worldwide** vs 213,767,576 cases last week.
- 4,525,907 people have died (2.1% of confirmed cases) and 194,287,167 have recovered (89%).
- **Europe:** 57,368,305 cases; 7-day avg growth of 142,942 vs 145,105 a week ago and 125,321 a month ago.
- **USA:** 39,396,156 cases; 7-day avg growth of 167,583 vs 155,753 a week ago and 85,459 a month ago.
- **Vaccines:** around 5.38 billion doses have been administered globally, of which 371 million in the **USA** and 533 million in the **EU**. 113 vaccines are in clinical evaluation and 184 vaccines are in preclinical evaluation.

**Global Confirmed Cases**




**Global Infected Status**




■ Deaths ■ Recovered ■ Active

**Global new cases per day**




**Global New Cases & Deaths**



— New cases, 7-day average (lhs) — New Deaths, 7-day average (rhs)


**daily cases & deaths per million, 7-day avg top 5 european economies\***



\* Overall daily cases and deaths per million people for France, Italy, Spain, Germany and the UK

**Percentage of people vaccinated**


source: Our World In Data



■ People Vaccinated ■ People Fully Vaccinated

**Percentage of people vaccinated**


with at least one dose



— USA — UK — Italy — France — Germany — Spain


**Covid-19 Effective Reproduction Rate (Rt)**

Source: Harvard Chan School of Public Health, 7-day avg




**share of positive Covid-19 tests**

7-day rolling average




**Covid-19 Govt. Response: Stringency Index**

Uni. of Oxford stringency index




**Covid-19 Govt. Response: Stringency Index**

Uni. of Oxford stringency index, EU: GDP weighted average of member states




**daily cases per million people, 7-day avg**

Selected Countries




**daily cases per million people, 7-day avg**

Emerging Markets




**daily cases per million people, 7-day avg**







Europe



**daily cases per million people, 7-day avg**

CEE






Country	TOP 10 most hit countries					
	Cases			Deaths		
	Total	last 7D avg	last month	Total	last 7D avg	last month
USA	39,396,156	+ 167,583	+ 145,196	642,081	+ 1,401	+ 975
India	32,856,863	+ 42,728	+ 37,360	439,559	+ 452	+ 473
Brazil	20,804,215	+ 22,668	+ 27,774	581,228	+ 643	+ 768
Russia	6,937,333	+ 18,918	+ 20,734	184,014	+ 799	+ 796
UK	6,825,074	+ 33,475	+ 31,154	132,742	+ 106	+ 98
France	6,783,329	+ 15,713	+ 20,568	114,577	+ 130	+ 90
Turkey	6,412,277	+ 19,799	+ 21,064	57,000	+ 255	+ 187
Argentina	5,190,948	+ 5,124	+ 7,690	112,005	+ 148	+ 188
Iran	5,025,233	+ 32,694	+ 35,934	108,393	+ 624	+ 579
Colombia	4,911,082	+ 1,990	+ 3,429	125,016	+ 77	+ 119

Country	Most hit regions					
	Cases			Deaths		
	Total	last 7D avg	last month	Total	last 7D avg	last month
Asia	68,382,238	+ 236,793	+ 245,317	1,136,164	+ 4,406	+ 4,964
Europe	57,368,305	+ 142,942	+ 140,530	1,073,575	+ 1,116	+ 828
North America	47,435,666	+ 203,349	+ 184,042	980,291	+ 2,371	+ 1,861
South America	36,959,928	+ 33,826	+ 43,435	1,131,698	+ 1,029	+ 1,265
Africa	7,891,089	+ 28,566	+ 34,966	197,340	+ 735	+ 825
Oceania	164,463	+ 1,600	+ 1,888	2,188	+ 23	+ 22
Others	723	-	-	15	-	-

\* Regional classification according to the United Nations Geoscheme; Russia included in Asia


### Google Mobility Index: Workplaces

Percentage change from baseline, 7-day avg




### Apple Mobility Index

Percentage change from baseline, 7-day avg



### OpenTable: Seated Diners at Restaurants

change from 2019, 7-day avg



COVID-19 candidate vaccines		
Stage	Phase	N°
Clinical Evaluation	4	8
	3	21
	2/3	10
	2	10
	1/2	26
	1	38
Total Clinical Evaluation		113
Preclinical Evaluation		184

\*Data from the World Health Organization landscape documents

Note: Data sources: WHO, CDC, ECDC, JHU, Worldometers.info, state and national government health departments, local media reports, Google Mobility Report, OpenTable, Bloomberg, Oxford University, OurWorldInData, Harvard Chan school of public health, Al Jazeera. The day is reset after midnight GMT+0. For additional information regarding the data collected and presented in this document please contact [mattia.mammarella@generali-invest.com](mailto:mattia.mammarella@generali-invest.com)

### Main news

- A research published in *The Lancet* found that the Delta variant doubles the risk of hospitalisation compared to the Alpha variant.
- A large-scale study by researchers from the University of Oxford has found that the risk of rare blood clotting after receiving first doses of AstraZeneca or Pfizer vaccines is far lower than that from the virus.
- Australia's capital city Canberra has extended its lockdown by two more weeks as cases are still rising.
- South African scientists have detected a new coronavirus variant with multiple mutations but are yet to establish whether it is more contagious or able to overcome the immunity provided by vaccines.
- The World Health Organization has warned that another 236,000 people could die from COVID-19 in Europe by December 1.
- Israel has begun offering a COVID-19 booster to children from 12-year-old.

# Imprint

<b>Head of Research</b>	Vincent Chaigneau (vincent.chaigneau@generali-invest.com)	
<b>Head of Macro &amp; Market Research:</b>	Dr. Thomas Hempell, CFA (thomas.hempell@generali-invest.com)	
<b>Team:</b>	Elisabeth Assmuth (elisabeth.assmuth@generali-invest.com) Elisa Belgacem (elisa.belgacem@generali-invest.com) Radomír Jáč (radomir.jac@generali.com) Jakub Krátký (jakub.kratky@generali.com) Michele Morganti (michele.morganti@generali-invest.com) Vladimir Oleinikov, CFA (vladimir.oleinikov@generali-invest.com) Dr. Martin Pohl (martin.pohl@generali.com) Dr. Thorsten Runde (thorsten.runde@generali-invest.com) Dr. Christoph Siepmann (christoph.siepmann@generali-invest.com) Dr. Florian Späte, CIIA (florian.spaete@generali-invest.com) Dr. Martin Wolburg, CIIA (martin.wolburg@generali-invest.com) Paolo Zanghieri, PhD (paolo.zanghieri@generali.com)	
<b>Head of Insurance and AM Research:</b>	Michele Morganti (michele.morganti@generali-invest.com)	
<b>Team:</b>	Raffaella Bagata (raffaella.bagata@generali.com) Alberto Cybo-Ottone, PhD (alberto.cybo@generali.com) Mattia Mammarella (mattia.mammarella@generali-invest.com) Roberto Menegato (roberto.menegato@generali.com) Giovanni Millo, PhD (giovanni.millo@generali.com) Antonio Salera, PhD (antonio.salera@generali.com) Cristiana Settimo (cristiana.settimo@generali.com) Federica Tartara, CFA (federica.tartara@generali.com)	
<b>Issued by:</b>	Generali Insurance Asset Management S.p.A., Research Department	
<b>In Italy:</b> Generali Insurance Asset Management S.p.A Società di gestione del risparmio  Piazza Tre Torri 20145 Milano MI, Italy  Via Niccolò Machiavelli, 4 34132 Trieste TS, Italy	<b>In France:</b> Generali Insurance Asset Management S.p.A Società di gestione del risparmio  2, Rue Pillet-Will 75009 Paris Cedex 09, France	<b>In Germany:</b> Generali Insurance Asset Management S.p.A. Società di gestione del risparmio  Tunisstraße 19-23 50667 Cologne, Germany

[www.generali-investments.com](http://www.generali-investments.com)

This document is based on information and opinions which Generali Insurance Asset Management S.p.A. Società di gestione del risparmio considers as reliable. However, no representation or warranty, expressed or implied, is made that such information or opinions are accurate or complete. Generali Insurance Asset Management S.p.A. Società di gestione del risparmio periodically updating the contents of this document, relieves itself from any responsibility concerning mistakes or omissions and shall not be considered responsible in case of possible changes or losses related to the improper use of the information herein provided. Opinions expressed in this document represent only the judgment of Generali Insurance Asset Management S.p.A. Società di gestione del risparmio and may be subject to any change without notification. They do not constitute an evaluation of any strategy or any investment in financial instruments. This document does not constitute an offer, solicitation or recommendation to buy or to sell financial instruments. Generali Insurance Asset Management S.p.A. Società di gestione del risparmio is not liable for any investment decision based on this document. Generali Investments may have taken, and may in the future take, investment decisions for the portfolios it manages which are contrary to the views expressed herein. Any reproduction, total or partial, of this document is prohibited without prior consent of Generali Insurance Asset Management S.p.A. Società di gestione del risparmio. Generali Investments is part of the Generali Group which was established in 1831 in Trieste as Assicurazioni Generali Austro-Italiane. Generali Investments is a commercial brand of Generali Investments Partners S.p.A. Società di gestione del risparmio, Generali Insurance Asset Management S.p.A. Società di gestione del risparmio, Generali Investments Luxembourg S.A. and Generali Investments Holding S.p.A..